An engineering strategy to target activated EGFR with CAR T cells
Markus Dobersberger, Delia Sumesgutner, Charlotte U. Zajc, Benjamin Salzer, Elisabeth Laurent, Dominik Emminger, Elise Sylvander, Elisabeth Lehner, Magdalena Teufl, Jacqueline Seigner, Madhusudhan Reddy Bobbili, Renate Kunert, Manfred Lehner, Michael W. Traxlmayr
Abstract
Chimeric antigen receptor (CAR) T cells have shown remarkable response rates in hematological malignancies. In contrast, CAR T cell treatment of solid tumors is associated with several challenges, in particular the expression of most tumor-associated antigens at lower levels in vital organs, resulting in on-target/off-tumor toxicities. Thus, innovative approaches to improve the tumor specificity of CAR T cells are urgently needed. Based on the observation that many human solid tumors activate epidermal growth factor receptor (EGFR) on their surface through secretion of EGFR ligands, we developed an engineering strategy for CAR-binding domains specifically directed against the ligand-activated conformation of EGFR. We show, in several experimental systems, that the generated binding domains indeed enable CAR T cells to distinguish between active and inactive EGFR. We anticipate that this engineering concept will be an important step forward to improve the tumor specificity of CAR T cells directed against EGFR-positive solid cancers.